Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$0.85 USD
+0.01 (1.01%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.85 0.00 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Prelude Therapeutics Incorporated has a market cap of $47.50M, which represents its share price of $0.84 multiplied by its outstanding shares number of 56.46M. As a small-cap company, PRLD's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PRLD 0.85 +0.01(1.01%)
Will PRLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
Other News for PRLD
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
Tracking Baker Brothers Portfolio - Q1 2025 Update
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc.
Prelude Therapeutics Appoints Paul Scherer as Director